Repligen Corporation to Present at Upcoming Investor Conferences
November 08, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present at...
Repligen Reports Third Quarter 2022 Financial Results and Updates Full Year 2022 Financial Guidance
November 01, 2022 07:30 ET
|
Repligen Corporation
Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organicDelivers base business growth of 29% for the...
Repligen Extends and Expands Long-Term Supply Agreement with Purolite for Affinity Ligands
November 01, 2022 07:00 ET
|
Repligen Corporation
WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that is has extended its long-term supply agreement with Purolite, An Ecolab Company...
Repligen to Report Third Quarter 2022 Financial Results
October 12, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its third quarter 2022 financial results on Tuesday, November 1,...
Repligen Expands Process Analytics Portfolio with DRS Daylight Solutions Agreement
September 19, 2022 16:01 ET
|
Repligen Corporation
WALTHAM, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced it has entered into a...
Repligen To Host Investor Day 2022
August 24, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a leading innovator of bioprocessing technologies and solutions, today announced that it will host “Repligen...
Repligen Reports Second Quarter 2022 Financial Results and Raises Full Year 2022 Financial Guidance
August 02, 2022 07:30 ET
|
Repligen Corporation
Record revenue of $207.6 million for the quarter, representing overall growth of 27% as reported and 32% at constant currency (year-over-year)Strong organic revenue growth of 29% and strong base...
Repligen to Report Second Quarter 2022 Financial Results
July 19, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its second quarter 2022 financial results on Tuesday, August 2,...
Repligen Appoints Dr. Konstantin Konstantinov to Board of Directors
May 26, 2022 16:30 ET
|
Repligen Corporation
WALTHAM, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of Konstantin Konstantinov, Ph.D., a life sciences and...
Repligen Corporation to Present at Upcoming Investor Conferences
May 25, 2022 07:30 ET
|
Repligen Corporation
WALTHAM, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be...